VivoSeq
Other

Neovascular AMD

0

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Neovascular AMD is an early-stage landscape with 0 programs across 8 companies. The most active players are Regeneron, Eyetech Pharmaceuticals, Chengdu Kanghong Biotech Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

0 programs

PreclinicalE

Eyetech Pharmaceuticals

0 programs

PreclinicalC

Chengdu Kanghong Biotech Co., Ltd.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

30

clinical trials

Completed22 · 73%
Terminated3 · 10%
Unknown status2 · 7%
Withdrawn2 · 7%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

30 trials

Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD
Not yet recruiting·GGuangzhou Jiayin Biotech Ltd·Phase 1/2·NCT07178249·60 enrolled
Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
Completed·UUniversity Health Network, Toronto·N/A·NCT02218177·30 enrolled
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
Completed·LLupin Ltd.·Phase 3·NCT04690556·600 enrolled
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
Completed·UUniversity of Miami·Phase 2·NCT00373659·40 enrolled
Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
Completed·VVista Klinik·Phase 4·NCT02309281·33 enrolled
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
Completed·Regeneron logoRegeneron·Phase 1·NCT00320775·51 enrolled
Phase II/III Study of Anti-VEGF in Neovascular AMD
Completed·EEyetech Pharmaceuticals·Phase 2/3·NCT00021736·540 enrolled
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
Completed·RRetinal Consultants Medical Group·Phase 2·NCT00426998·30 enrolled
Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD
Completed·AAlteogen, Inc.·Phase 1·NCT04058535·28 enrolled
A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD
Completed·CChengdu Kanghong Biotech Co., Ltd.·Phase 2·NCT01157715·122 enrolled
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
Completed·UUniversity of Miami·Phase 2·NCT00344227·40 enrolled
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
Completed·GSK logoGSK·Phase 2·NCT00612456·70 enrolled
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
Completed·TThe University of Hong Kong·Phase 4·NCT05710471·30 enrolled
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
Completed·—·Phase 2·NCT02462889·128 enrolled
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
Completed·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04370379·18 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)